NCCN Guidelines

Two quadruplet therapies have been approved by the FDA as first-line treatment for patients with newly diagnosed multiple myeloma (NDMM) and updated in the NCCN guidelines for the treatment of multiple myeloma.

Sacituzumab govitecan-hziy has been granted full FDA approval for the treatment of metastatic triple-negative breast cancer. It has also been included in the NCCN Breast Cancer Guidelines based on convincing clinical evidence.

The updated National Comprehensive Cancer Network (NCCN) guideline for non–small-cell lung cancer (NSCLC; version 3.2019) is focused on improving patient outcomes with immunotherapy.

Hereditary breast and ovarian cancer syndrome and Lynch syndrome (HBOC/LS) are the 2 most common inherited cancer predisposition syndromes.

Options for the treatment of patients with advanced hormone receptor (HR)-positive, HER2-negative breast cancer are expanding.

The discontinuation of a tyrosine kinase inhibitor (TKI) is considered safe and appropriate in consenting patients with chronic-phase chronic myeloid leukemia (CML) under specific circumstances and with careful molecular monitoring, according to the updated National Comprehensive Cancer Network (NCCN) management guideline for CML.

Germline testing should now be considered for any patient with pancreatic cancer, and molecular analysis of tumors should be considered in patients with metastatic disease, according to the most recent National Comprehensive Cancer Network (NCCN) guideline (version 1.2019) for the management of pancreatic cancer.

More targeted therapy options make their way into the updated guideline (version 1.2019) from the National Comprehensive Cancer Network (NCCN) for the management of metastatic colorectal cancer (CRC).

New prostate cancer guidelines issued by the National Comprehensive Cancer Network (NCCN) continue to support early detection efforts in well-informed, healthy men while acknowledging that optimal screening of high-risk patients is not completely known. The guidelines also support the use of active surveillance in men who have low-risk prostate cancer.

HIV status alone should not be used for cancer treatment decision-making, according to the first guidelines from the National Comprehensive Cancer Network (NCCN) on the management of cancer in persons infected with HIV